| Literature DB >> 26693492 |
Léa Campos de Oliveira1, Anna Carla Goldberg2, Maria Lucia Carnevale Marin3, Karina Rosa Schneidwind4, Amanda Farage Frade5, Jorge Kalil6, Irene Kasue Miura4, Renata Pereira Sustovich Pugliese4, Vera Lucia Baggio Danesi4, Gilda Porta4.
Abstract
Pediatric autoimmune hepatitis (AIH) patients present hypergammaglobulinemia, periportal CD8(+) cytotoxic T cell infiltration, and cirrhosis. Autoantibody profile defines AIH types 1 and 2 in addition to strong association with HLA-DRB1. We previously detected increased IgE serum levels and sought to compare clinical and histological features according to IgE levels in AIH (n = 74, ages 1-14 years) patients. Additionally, we typed 117 patients and 227 controls for functional polymorphisms of IL4, IL13, IL5, and IL4RA genes involved in IgE switching and eosinophil maturation that might contribute to overall genetic susceptibility to AIH. Serum IgE levels were high in 55% of AIH-1, but only in 12% of AIH-2 (P = 0.003) patients. Liver IgE was present in 91.3% of AIH-1 patients. The A alleles at both IL13 rs20541 and IL4RA rs1805011 were associated with AIH-1 (P = 0.024, OR = 1.55 and P < 0.0001, OR = 2.15, resp.). Furthermore, individuals presenting homozygosis for the A allele at IL4RA rs1805011 and HLA-DRB1(∗)03 and/or (∗)13 allele had sixfold greater risk to develop the disease (OR = 14.00, P < 0.001). The novel association suggests an additional role for IgE-linked immune response genes in the pathogenesis of AIH.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26693492 PMCID: PMC4674601 DOI: 10.1155/2015/679813
Source DB: PubMed Journal: J Immunol Res ISSN: 2314-7156 Impact factor: 4.818
Clinical and laboratory findings of children with type 1 and type 2 autoimmune hepatitis.
| AIH-1 | AIH-2 | |
|---|---|---|
|
|
| |
|
| ||
| Age onset; median (min–max) | 8.2 (1.6–15.2) | 4.8 (11.1–9.0) |
| Sex; | 78/39 | 21/3 |
| Onset; | 98/19 | 20/4 |
| Concurrent autoimmune disease1; | 15 (12.8) | 3 (12.5) |
| Autoimmune diseases in relatives2; | 23 (19.6) | 11 (45.8) |
|
| ||
|
| ||
| AA: type 1, SMA/ANA/SMA + ANA; type 2, LKM ( | 64/7/46 | 24 |
| Alanine aminotransferase IU/L (× upper normal limit); median (min-max) | 18 (2–128) | 28 (4–85) |
| Albumin g/dL; median (min-max) | 3.3 (2.2–5.1) | 3.5 (2.6–4.7) |
| Bilirubin mg/dL; median (min-max) | 3.3 (0.3–27.2) | 5.8 (0.6–35) |
|
| 3.4 (0.9–6.3) | 3.3 (0.9–4.8) |
| IgE IU/mL; median (min-max) | 96 (11–2245) | 65 (6–560) |
|
| ||
|
| ||
| Cirrhosis; | 64/41 | 10/10 |
| Not done | 12 | 4 |
F = female; M = male; AA = autoantibody; SMA = smooth muscle antibody; ANA = antinuclear antibody; LKM = Liver Kidney Microsomal; n = number of individuals.
Normal albumin = 3.5–5.0 g/dL; normal bilirubin ≤ 1.1 mg/dL; normal γ-globulin = 0.7–1.6 g/dL; normal IgE = 20–100 IU/mL.
1Vitiligo, thyroiditis, diabetes mellitus, psoriasis, or Behçet's disease.
2First degree relatives.
Figure 1Immunoglobulins concentrations according to autoimmune hepatitis type. (a) IgA (g/dL); (b) IgM (g/dL); (c) IgG (g/dL), and (d) IgE (UI/mL). The immunoglobulins concentrations were assessed by nephelometry. Statistical analysis by Mann-Whitney nonparametric test (for medians).
Semiquantitative assessment of the histopathological variables by serum IgE levels in AIH-1 and AIH-2 patients.
| Histopathological variables | Score | AIH-1 | AIH-2 | ||
|---|---|---|---|---|---|
| IgE | IgE | ||||
| Normal | Increased | Normal | Increased | ||
|
|
|
|
| ||
| Structural changes | 1-2 | 2 (7) | 1 (3) | 1 (9) | 0 (0) |
| 3 | 2 (7) | 2 (6) | 1 (9) | 1 (50) | |
| 4 | 23 (86) | 30 (91) | 9 (82) | 1 (50) | |
|
| |||||
| Portal inflammation | 1-2 | 8 (30) | 11 (33) | 5 (45) | 0 (0) |
| 3 | 15 (55) | 11 (33) | 4 (36) | 1 (50) | |
| 4 | 4 (15) | 11 (33) | 2 (18) | 1 (50) | |
|
| |||||
| Periportal inflammation | 1-2 | 6 (22) | 7 (21) | 3 (27) | 0 (0) |
| 3 | 11 (41) | 10 (30) | 3 (27) | 1 (50) | |
| 4 | 10 (37) | 19 (55) | 5 (46) | 1 (50) | |
|
| |||||
| Panacinar necrosis | Present | 12 (44) | 21 (64) | 3 (27) | 2 (100) |
|
| |||||
| Plasmocytes | Present | 20 (74) | 27 (82) | 8 (73) | 1 (50) |
|
| |||||
| Eosinophils | Present | 16 (59) | 19 (58) | 7 (64) | 1 (50) |
|
| |||||
| Rosettes | Present | 24 (89) | 29 (88) | 10 (91) | 2 (100) |
1 = minimal portal fibrosis; 2 = moderate portal fibrosis; 3 = bridging fibrosis; 4 = cirrhosis.
Immunohistochemical analysis for tissue IgE, liver-infiltrating T and B lymphocytes, and NK cells in the liver of AIH-1 patients, grouped according to serum IgE levels.
| Infiltrate | AIH-1 | |
|---|---|---|
| IgE serum levels | ||
| Normal | Increased | |
|
|
| |
| IgE | ||
| Negative | 3 (12) | 1 (5) |
| Low | 11 (42) | 11 (55) |
| Moderate/elevated | 8 (31) | 8 (40) |
| Not done | 4 (15) | 0 |
|
| ||
| CD3 | ||
| Negative | 0 | 0 |
| Low | 6 (23) | 6 (30) |
| Moderate/elevated | 20 (77) | 14 (70) |
| Not done | 0 | 0 |
|
| ||
| CD8 | ||
| Negative | 0 | 1 (5) |
| Low | 14 (54) | 9 (45) |
| Moderate/elevated | 10 (38) | 9 (45) |
| Not done | 2 (8) | 1 (5) |
|
| ||
| CD4 | ||
| Negative | 6 (23) | 6 (30) |
| Low | 9 (35) | 7 (35) |
| Moderate/elevated | 11 (42) | 6 (30) |
| Not done | 0 | 1 (5) |
|
| ||
| CD20 | ||
| Negative | 1 (4) | 1 (5) |
| Low | 11 (42) | 10 (50) |
| Moderate/elevated | 14 (54) | 8 (40) |
| Not done | 0 | 1 (5) |
|
| ||
| CD16 | ||
| Negative | 0 | 0 |
| Low | 13 (50) | 11 (55) |
| Moderate/elevated | 13 (50) | 5 (25) |
| Not done | 0 | 4 (20) |
Genotype and allele frequencies of IL13 rs20541 and IL4RA rs1805011 in children with type 1 autoimmune hepatitis (AIH-1) and in healthy controls (HC).
| AIH-1 | HC |
| OR | 95% CI | |
|---|---|---|---|---|---|
|
|
| ||||
|
|
|
| |||
|
| |||||
| Genotype | |||||
| AA | 18 (15) | 6 (4) | |||
| AG | 37 (32) | 60 (38) | 0.003 | ||
| GG | 62 (53) | 94 (58) | |||
| AA versus AG+GG | <0.001 | 4.62 | 1.77–12.04 | ||
| Allele | |||||
| A | 73 (31) | 72 (23) | 0.024 | 1.55 | 1.06–2.27 |
| G | 161 (69) | 248 (77) | |||
|
| |||||
|
|
|
| |||
|
| |||||
| Genotype | |||||
| AA | 41 (47) | 40 (19) | |||
| AG | 37 (42) | 129 (61) | <0.001 | ||
| GG | 10 (11) | 43 (20) | |||
| AA versus AG+GG | <0.001 | 3.75 | 2.18–6.45 | ||
| Allele | |||||
| A | 119 (68) | 209 (49) | <0.001 | 2.15 | 1.49–3.11 |
| G | 57 (32) | 215 (51) | |||
IL13 codon 110 (rs20541): A allele = Q (glutamic acid) and G allele = R (arginine); IL4RA codon 50 (rs1805011): A allele = I (isoleucine) and G allele = V (valine); n = number of individuals; OR = odds ratio; CI = confidence interval.
Multivariate analysis of factors associated with AIH-1, using three different models.
| Dependent variable |
| OR | 95% CI | |
|---|---|---|---|---|
| AIH-1 | ||||
| Model 1 | ||||
|
| Different from 03 and/or 13 | <0.001 | 8.28 | 3.46–19.82 |
| 03 and/or 13 | ||||
|
| AG plus GG | 0.002 | 9.45 | 2.28–39.18 |
| AA | ||||
|
| AG plus GG | 0.001 | 3.72 | 1.78–7.77 |
| AA | ||||
|
| ||||
| IL5 rs2069812 | ||||
| Model 2 | ||||
| Treatment suspension | Yesa | 0.004 | 6.41 | 1.83–22.44 |
| No | ||||
|
| ||||
| IgE levels | ||||
| Model 3 | ||||
|
| TT and GT | 0.022 | 7.42 | 1.33–41.34 |
| GG | ||||
Dependent variable in model 1: AIH-1 susceptibility.
Dependent variable in model 2: IL5 rs2069812.
Dependent variable in model 3: IgE levels.
IL13 codon 110 (rs20541): A allele = Q (glutamic acid) and G allele = R (arginine); IL4RA codon 50 (rs1805011): A allele = I (isoleucine) and G allele = V (valine).
aHomozigosis for T allele.